Lemborexant
一、 Product Overview
Lemborexant is a is an orexin receptor antagonist indicated for the treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.It was approved by the US Food and Drug Administration (FDA) on December 20, 2019.
二、Main products
Description | Structural Formula | CAS No. | Category |
Lemborexant |
| 1369764-02-2 | API |
2,4-dimethylpyrimidin-5-ol |
| 412003-95-3 | intermediates |
((1R,2S)-2-(3-fluorophenyl)-2-((tosyloxy)methyl)cyclopropyl)methyl acetate |
| 1450904-92-3 | intermediates |
Note: Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes patent infringement and its liability is at buyer's risk.